TransMedics Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
TransMedics Group (TMDX) PT Raised to $200 at Oppenheimer
August 1, 2024 6:04 AM EDTOppenheimer analyst Suraj Kalia raised the price target on TransMedics Group (NASDAQ: TMDX) to $200.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "TransMedics reported 2Q24 revs. of $114.3M, blowing past our/consensus $100.2M/$98.8M estimates. In Q2, ~126 (+21 seq.; ~55 liver, ~57 heart, ~14 lung) transplant... More
